Thrivent Financial for Lutherans Trims Stock Position in CareDx, Inc (NASDAQ:CDNA)

Thrivent Financial for Lutherans decreased its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 28.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 57,939 shares of the company's stock after selling 23,392 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.11% of CareDx worth $1,240,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Virtue Capital Management LLC bought a new stake in shares of CareDx during the third quarter valued at approximately $755,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in CareDx in the 3rd quarter valued at $1,671,000. Geode Capital Management LLC lifted its stake in CareDx by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company's stock worth $38,343,000 after purchasing an additional 32,141 shares in the last quarter. Swiss National Bank boosted its holdings in shares of CareDx by 1.9% during the 4th quarter. Swiss National Bank now owns 98,600 shares of the company's stock valued at $2,111,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of CareDx by 123.8% during the 3rd quarter. Barclays PLC now owns 98,505 shares of the company's stock valued at $3,075,000 after purchasing an additional 54,482 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and decreased their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Stephens reaffirmed an "overweight" rating and set a $40.00 price objective on shares of CareDx in a report on Thursday, February 27th. HC Wainwright reduced their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.83.

Remove Ads

CareDx Trading Down 0.5 %

Shares of CDNA stock traded down $0.09 during trading hours on Friday, reaching $17.28. 1,029,539 shares of the stock were exchanged, compared to its average volume of 850,908. The firm has a market capitalization of $957.76 million, a price-to-earnings ratio of -6.40 and a beta of 2.17. CareDx, Inc has a 12-month low of $7.42 and a 12-month high of $34.84. The company's 50-day moving average price is $20.90 and its 200-day moving average price is $23.28.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. On average, sell-side analysts expect that CareDx, Inc will post -0.9 EPS for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.